| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/20/2005 | CA2531419A1 Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment |
| 01/20/2005 | CA2531235A1 Applications of a new class of enzymes: sulfiredoxines. |
| 01/20/2005 | CA2530967A1 Inhibition of stress-induced ligand-dependent egfr activation |
| 01/20/2005 | CA2530529A1 Compositions and methods for selective dissolution of nascent intravascular blood clots |
| 01/20/2005 | CA2528465A1 Compositions and methods for enhanced mucosal delivery of growth hormone |
| 01/20/2005 | CA2526402A1 Blys antagonists and uses thereof |
| 01/20/2005 | CA2525091A1 Water-soluble shps as novel alkylating agents |
| 01/19/2005 | EP1498480A2 Human hydrolytic enzymes |
| 01/19/2005 | EP1498425A1 Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions |
| 01/19/2005 | EP1498422A1 C5a Receptor Antagonists |
| 01/19/2005 | EP1498421A1 Gamma-secretase inhibitors |
| 01/19/2005 | EP1498150A1 Delivery of solid drug compositions |
| 01/19/2005 | EP1498145A1 DECOY FOR TREATING AND/OR PREVENTING Th2 CYTOKINE-ASSOCIATED ALLERGIC DISEASE, GATA3 MUTANT PROTEIN AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| 01/19/2005 | EP1498135A1 Dental viscous pharmaceutical containing basic fibroblast growth factor |
| 01/19/2005 | EP1498134A1 Helicobacter pylori adhesion inhibitor |
| 01/19/2005 | EP1498133A1 Use of a pak inhibitor for the treatment of a joint disease |
| 01/19/2005 | EP1498128A1 Medicinal compositions containing phtocrosslinkable chitosan derivative |
| 01/19/2005 | EP1498126A1 Neurotrophic factor production accelerator |
| 01/19/2005 | EP1498124A2 The use of inhibitors of the renin-angiotensin system |
| 01/19/2005 | EP1498115A1 Preparation of particles for inhalation |
| 01/19/2005 | EP1497797A2 2150, a human protein kinase family member and uses therefor |
| 01/19/2005 | EP1497658A2 Protein involved in cancer |
| 01/19/2005 | EP1497656A2 Diagnosis of carcinoma using raig1 polypeptides |
| 01/19/2005 | EP1497654A2 Immunoglobulin e vaccines and methods of use thereof |
| 01/19/2005 | EP1497649A2 Antibodies specific for mucin polypeptide |
| 01/19/2005 | EP1497467A2 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof |
| 01/19/2005 | EP1497466A2 Binary or polynary targeting and uses thereof |
| 01/19/2005 | EP1497462A2 Genomic screen for epigenetically silenced genes associated with cancer |
| 01/19/2005 | EP1497436A1 Compositions for delivering enzymes involved in amino acid metabolism using recombinant adeno-associated virus virons (raav virons), and method and use for treating amino acid metabolic disorders using such raav virons |
| 01/19/2005 | EP1497426A2 Co-stimulatory molecules |
| 01/19/2005 | EP1497425A2 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
| 01/19/2005 | EP1497419A1 Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof |
| 01/19/2005 | EP1497334A2 Protein stabilisation using chaperone proteins |
| 01/19/2005 | EP1497330A2 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
| 01/19/2005 | EP1497329A1 Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases |
| 01/19/2005 | EP1497328A2 Regulation of human transient receptor potential channel |
| 01/19/2005 | EP1497326A1 Prothrombin activating protein |
| 01/19/2005 | EP1497323A1 Multiple branch peptide constructions comprising from 2 to 16 branches of the peptide rqgys or from 8 to 16 branches of the peptide rqgy providing from the hiv gp41 glycoprotein |
| 01/19/2005 | EP1497322A2 Treatment of infections and other disorders |
| 01/19/2005 | EP1497319A2 Cell adhesion and extracellular matrix proteins |
| 01/19/2005 | EP1497317A2 Dipeptidic growth hormone secretagogues |
| 01/19/2005 | EP1497316A2 Growth hormone secretagogues |
| 01/19/2005 | EP1497315A2 Nucleic acid-associated proteins |
| 01/19/2005 | EP1497313A2 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease |
| 01/19/2005 | EP1497306A1 Alternatively spliced nucleic acid molecules |
| 01/19/2005 | EP1497305A2 Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes |
| 01/19/2005 | EP1497283A1 Maleic acid salt of(2s)-n-(5(amino(imino)methyl)-2-thienyl)methyl-1-(2r)-2-((2r)-2-((carboxymethyl)amino)3,3-diphenylpropanoyl)-2-pyrrolidine carboxamide and a process for |
| 01/19/2005 | EP1497282A2 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease |
| 01/19/2005 | EP1497271A1 Indane acetic acid derivatives and their use as pharmaceutical agents |
| 01/19/2005 | EP1496995A1 Method and apparatus for ultrasound treatment of connective tissue |
| 01/19/2005 | EP1496979A2 Protamine-adenoviral vector complexes and methods of use |
| 01/19/2005 | EP1496967A1 Therapeutic dry powder preparation |
| 01/19/2005 | EP1496951A1 Wound dressings comprising hydrated hydrogels and enzymes |
| 01/19/2005 | EP1496943A2 Oligomeric compounds having modified phosphate groups |
| 01/19/2005 | EP1496940A2 Methods of treating diabetes using pde 11a inhibitors |
| 01/19/2005 | EP1496937A2 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/19/2005 | EP1496936A1 Intraventricular hemorrhage thrombolysis |
| 01/19/2005 | EP1496935A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/19/2005 | EP1496934A2 Adjuvant enhanced immunotherapy |
| 01/19/2005 | EP1496933A2 Use of interleukin-19 to treat ovarian cancer |
| 01/19/2005 | EP1496932A2 Anti-hiv composition, production method thereof and medicament |
| 01/19/2005 | EP1496931A1 Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| 01/19/2005 | EP1496930A2 G-type peptides to ameliorate atherosclerosis |
| 01/19/2005 | EP1496929A1 Use of c5a receptor antagonist in the treatment of fibrosis |
| 01/19/2005 | EP1496926A1 Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| 01/19/2005 | EP1496925A2 Use of interleukin-24 to treat ovarian cancer |
| 01/19/2005 | EP1496924A2 Treatment of gastroparesis |
| 01/19/2005 | EP1496893A2 Neuroprotectant methods, compositions, and screening methods thereof |
| 01/19/2005 | EP1496879A1 Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2 |
| 01/19/2005 | EP1496877A2 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states |
| 01/19/2005 | EP1496851A1 Oral care products containing ovomucin |
| 01/19/2005 | EP1496835A2 Compositions and methods for systemic inhibition of cartilage degradation |
| 01/19/2005 | EP1496834A2 High affinity integrin polypeptides and uses thereof |
| 01/19/2005 | EP1496743A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/19/2005 | EP1392366A4 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 01/19/2005 | EP1379283A4 Identification of target-specific folding sites in peptides and proteins |
| 01/19/2005 | EP1318721A4 Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions |
| 01/19/2005 | EP1287018B1 Thrombin inhibitors |
| 01/19/2005 | EP1165493B1 Nitrogen mustard compounds and prodrugs therefor |
| 01/19/2005 | EP1100589B1 Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity |
| 01/19/2005 | EP0963196B1 Hyaluronic drug delivery system |
| 01/19/2005 | EP0954282B1 Preparation of particles for inhalation |
| 01/19/2005 | EP0941116B1 Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device |
| 01/19/2005 | EP0933995B8 Method of treating endothelial injury |
| 01/19/2005 | EP0862580B1 Streptoccal inhibitor of complement-mediated lysis, protein sic |
| 01/19/2005 | EP0789588B1 Method for making a medicament for treating secondary immunodeficiency |
| 01/19/2005 | EP0784429B1 Therapeutic combinations of venous dilators and arterial dilators |
| 01/19/2005 | EP0545946B1 Growth-promoting agent |
| 01/19/2005 | CN1568373A RNA interference mediating small rna molecules |
| 01/19/2005 | CN1568369A Hybrid interferon/interferon Tau proteins, compositions and methods of use |
| 01/19/2005 | CN1568330A Glycosylphosphatidylinositol containing polypeptides |
| 01/19/2005 | CN1568329A Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease |
| 01/19/2005 | CN1568325A Cross-linked glycopeptide-cephalosporin antibiotics |
| 01/19/2005 | CN1568306A Hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity |
| 01/19/2005 | CN1568199A Drugs ameliorating hypo-HDL cholesterolemia |
| 01/19/2005 | CN1568196A Nutrient therapy for immuno-compromised patients |
| 01/19/2005 | CN1568195A Peptide YY and peptide YY agonists for treatment of metabolic disorders |
| 01/19/2005 | CN1568194A Modulation of smooth muscle cell proliferation |
| 01/19/2005 | CN1568193A Use of il-18 inhibitors in hypersensitivity disorders |
| 01/19/2005 | CN1568192A Kahalalide F formulation |